

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 May 2008 (08.05.2008)

PCT

(10) International Publication Number
WO 2008/053300 A1

(51) International Patent Classification:

C07D 231/54 (2006.01) **A61K 31/416** (2006.01)
C07D 401/04 (2006.01) **A61K 31/4162** (2006.01)
C07D 405/04 (2006.01) **A61P 9/12** (2006.01)
C07D 493/04 (2006.01)

(21) International Application Number:

PCT/IB2007/003207

(22) International Filing Date: 17 October 2007 (17.10.2007)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/863,606 31 October 2006 (31.10.2006) US

(71) Applicant (for all designated States except US): **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MEYERS, Marvin Jay** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). **ARRANCET, Graciela Barbieri** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). **CHEN, Xiangyang** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). **HOCKERMAN, Susan Landis** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). **LONG, Scott, Allen** [US/US];

Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). **MAHONEY, Matthew, William** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). **REITZ, David, Bruce** [US/US]; 14814 Pleasant Ridge Court, Chesterfield, MO 63017 (US). **RICO, Joseph Gerace** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US).

(74) Agent: **FULLER, Grover, F., Jr.**; c/o George, Nancy, McGraw, Pfizer Inc. MS 8260-1615, Eastern Point Road, Groton, CT 06340 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(54) Title: PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS



(57) Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R1, R2, R3A, R3B, R4, R5, R6, R7, R8, and X are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, and intermediates are also disclosed.